Serene, LLC

Clear Vascular Inc.

Other

Theragenics Corporation

Snip Holdings, Incorporated

Neurosn, Inc.

Tcnet, LLC

Stevenson, Nigel R.

Nigel Raymond Stevenson

Jaime Simon

Gilbert R Gonzales

Ian Martin Horn

Druce K Crump

Lee O Heflinger

Zechariah David Sandlin

St George George

John M Dawson

George St George

Described are methods and compositions for processes of preparing a radioactive solution of Sn-117m tetraiodide. Aspects include reacting a radioactive solid Sn containing Sn-117m with a solution of Iin an organic solvent at a temperature and for a duration sufficient to result in the formation of Sn-117m tetraiodide. Then, the organic solvent is removed by evaporation to leave dry Sn-117m tetraiodide. The organic solvent is a low boiling point solvent capable of dissolving Iand Sn tetraiodide. The organic solvent is selected from the group consisting of an alcohol and a chlorinated solvent. In embodiments may be selected from the group consisting of dichloromethane, trichloromethane, tetrachloromethane, or mixtures thereof. In embodiments, the organic solvent excludes alcohol. The Imay be in a slight molar excess to the radioactive solid Sn. The method may further include distilling the reactants to remove excess Ifrom the distillate.

Process for producing radioactive dry Sn-117M tetraiodide radiochemical

A method of purifying a high specific activity Sn-117m composition is provided that includes extracting an iodide complex of Sn-117m with an organic solvent from an acidic aqueous cadmium solution comprising a dissolved irradiated cadmium target, an acid, and a source of iodide. The organic solvent layer comprising the iodide complex of Sn-117m is substantially reduced in cadmium content. The Sn-117m may be back extracted into an aqueous solution.

High purity SN-117M compositions and methods of preparing same

Tin-117m somatostatin analogues or antagonist are used to treat tumors and symptoms associated with these tumors which express somatostatin receptors, such as gastroenteropancreatic neuroendocrine tumors. The tin-117m somatostatin receptor binding compounds can be administered at a dosage which is effectively apoptotic and not necrotic. Also, if desired, it can be administered at a dose that is necrotic and/or induces necrosis, but only to cells within 290 microns of the tin-117m atom. A novel somatostatin analogue is also disclosed, as well as novel methods to produce the tin labeled analogues and antagonists.

Tin-117m somatostatin receptor binding compounds and methods

Alzheimer's disease is treated by attacking hyperactive microglia preferably before excessive beta amyloid is built up by administering tin-117m-DOTA annexin V. This compound in low radioactive doses selectively binds to the aged hyperactive microglia and emits a conversion electron which effectively induces apoptosis in the hyperactive microglia. A follow-up treatment of tin-annexin A1 can be administered to repair the blood brain barrier. The annexin A1 assists in the repair of the blood-brain barrier and the associated tin-117m will induce apoptosis in aged hyperactive microglia associated with the blood brain barrier.

Method of diagnosing and treating Alzheimer's disease

Tin-117m somatoostatin analogs or antagonist are used to treat tumors and symptoms associated with these tumors which express somatostatin receptors, such as gastroenteropancreatic neuroendocrine tumors. The tin-117m somatostatin receptor binding compounds can be administered at a dosage which is effectively apoptotic and not necrotic. Also, if desired, it can be administered at a dose that is necrotic and/or induces necrosis, but only to cells within 290 microns of the tin-117m atom. A novel somatostatin analog is also disclosed, as well as novel methods to produce the tin labeled analogs and antagonists.

Methods for producing Tc-99m radioisotope by proton irradiation of a fluid target matrix. A method of producing Tc-99m includes irradiating a fluid target matrix comprising Mo-100 with a proton beam to transform at least a portion of Mo-100 to Tc-99m. Optionally, the fluid target matrix further includes at least one of O-18, O-16, or N-14, which upon exposure to the proton beam concurrently transform at least a portion of O-18 to F-18, at least a portion of O-16 to N-13, at least a portion of the O-16 to O-15, or at least a portion of N-14 to C-11. The method further includes isolating Tc-99m and optionally at least one of F-18, N-13, O-15, or C-11 from the irradiated fluid target matrix. An additional source of Tc-99m is available from the decay of Mo-99 that is co-produced from the Mo-100 during irradiation with the proton beam.

Tc-99m produced by proton irradiation of a fluid target system

Methods for producing a radioisotope by a charged particle irradiation of a fluid target matrix are provided. A method of producing a radioisotope includes irradiating a fluid target matrix comprising a compound of a target isotope with a charged particle beam to transform at least a portion of the target isotope to the radioisotope, and isolating the radioisotope from the irradiated fluid target matrix. The target isotope may be an isotope of cadmium, an isotope of thallium, an isotope of zinc, an isotope of gallium, an isotope of tellurium, an isotope of molybdenum, an isotope of rhodium, an isotope of selenium, an isotope of nickel, an isotope of yttrium, an isotope of strontium, an isotope of bismuth, an isotope of tungsten, and an isotope of titanium, provided that the target isotope is not Mo-100.

General radioisotope production method employing PET-style target systems

Compositions of high specific activitySn with specific activity of greater than 100 Ci/g Sn and methods of producing the same. The method includes exposingCd to an &#x3b1;-particle beam of sufficient incident kinetic energy and duration to convert a portion of theCd toSn to form an irradiated material. The irradiated material is dissolved to form an intermediate solution containingSn andCd. TheSn is separated from theCd to yield high specific activitySn.

[object Object]

Compositions of high specific activity SN-117M and methods of preparing the same

A method for associating information with an article, an isotopic labeling composition to label an article with information using at least two different isotopes of an element, and an article labeled with the labeling composition. In the labeling composition, the isotopes of the labeling composition have an abundance ratio that is detectably different from the natural abundance ratio thereof. By detecting the abundance ratio(s) of the isotopes in the labeling composition, via laser ablation/magnetic spectroscopy, an NQR spectrometer, an NMR spectrometer, an IR spectrometer, or a microwave spectrometer, information about the article can be determined. The method and labeling composition may be used to identify, authenticate or determine the source or origin of an article or to provide detailed information about an article.

Growing community of inventors

Sugar Hill, GA, United States of America

Nigel Raymond Stevenson